1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Getinge AB (publ)

Getinge AB (publ)

GNGBY
Getinge AB (publ)US flagOther OTC
20.76
USD
+0.77
- -
5.65BMarket Cap
Getinge AB (publ)
GNGBY
(Other OTC)

Recent

price

20.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
87.71
86.46
95.93
100.04
105.5
119.61
91.7
89.72
88.75
97.51
109.48
99.31
103.87
116.85
127.62
128.38
130.33
Revenue per Share
9.01
10
9.97
9.04
5.67
5.5
4.91
5.49
-3.55
4.49
11.89
10.9
9.15
8.86
6.01
8.29
5.47
Basic EPS, GAAP
11.32
8.85
7.84
7.36
10.2
6.76
9.29
4.39
9.19
9.59
22.59
20.67
8.19
5.89
12
9.67
9.93
Free Cash Flow per Basic Share
2.59
3.07
3.54
3.91
3.93
2.73
2.83
1.97
1.56
1.09
1.59
3.15
4.08
4.34
4.5
4.65
4.68
Dividend per Share
32.27
39.65
44.98
49.7
49.59
52.38
56.22
49.57
41.04
43.11
53.45
61.37
69.51
73.42
75.13
79.45
73.76
Book Value per Share
-23.64
-39.01
-38.35
-33.89
-44.98
-43.32
-45.86
-12.92
-16.31
-12.15
-2.2
3.77
12.64
-0.98
-22.14
-14.76
-20.82
Tangible Book Value per Share
253
253
253
253
253
253
242
251
272
272
272
272
272
272
272
272
272
Basic Weighted Avg Shares
22,172
21,854
24,248
25,287
26,669
30,235
22,170
22,495
24,172
26,559
29,819
27,049
28,291
31,827
34,759
34,968
35,499
Sales/Revenue/Turnover
17.45
18.76
17.46
16.46
14.42
11.31
12.08
10.03
-1.17
10.19
16.87
16.07
13.7
11.61
10.63
12.77
10.8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
2,703
2,609
1,808
2,223
2,467
1,814
2,027
2,093
2,422
2,250
2,538
Depreciation Expense
2,277
2,529
2,521
2,285
1,433
1,390
1,188
1,376
-967
1,222
3,239
2,970
2,491
2,412
1,638
2,258
1,490
Net Income, GAAP
26.83
26.34
26.34
27.21
27.13
27.04
26.15
- -
- -
34.21
27.05
28.34
27.53
27.37
27.52
27.63
27.96
Effective Tax Rate (%)
10.27
11.57
10.4
9.04
5.37
4.6
5.36
6.12
-4
4.6
10.86
10.98
8.8
7.58
4.71
6.46
4.2
Profit Margin (%)
4,935
5,241
3,070
4,029
1,630
3,880
3,896
2,292
4,143
4,630
7,643
4,459
7,113
3,462
3,115
4,185
2,880
Working Capital
11,411
15,121
13,163
13,566
14,378
16,006
15,914
4,962
7,378
7,068
7,687
3,495
5,031
4,960
8,280
8,922
8,975
LT Debt
13,248
14,636
15,200
16,560
18,694
19,593
20,916
19,806
19,655
20,973
21,486
25,176
30,453
30,403
33,210
29,493
29,018
Total Equity
10.32
10.54
9.71
9.11
7.68
6.24
4.76
- -
- -
5.79
11.68
10.12
8.48
7.14
6.47
7.6
6.86
Return on Invested Capital (%)
12.27
12.01
10.46
9.19
5.97
5.39
4.35
- -
- -
6.54
14.28
13.06
11.22
10.23
6.9
8.5
4.89
Return on Capital (%)
30.51
27.82
23.57
19.09
11.42
10.79
8.85
10.58
-8.19
10.66
24.63
18.99
13.98
12.39
8.1
10.73
7.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,447
2,219
2,194
LT Borrowings
6,971
8,118
7,910
LT Finance Leases
1,309
1,145
1,065
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
272
272
272
Market Capitalization
49,602
59,004
51,781

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
18,162
18,164
15,733
Cash, Cash Equivalents & STI
2,961
4,203
1,945
Accounts Receivable, Net
6,348
5,265
4,785
Inventories
6,590
6,650
6,793
Total Current Liabilities
15,047
13,888
12,853
Payables & Accruals
- -
- -
- -
ST Debt
2,447
2,219
2,194
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.59%
7.2%
-11.19%
Free Cash Flow
23.52%
-2.52%
-19.37%
Net Income, GAAP
-25.21%
-4.37%
37.85%
Sales/Revenue/Turnover
2.2%
3.52%
0.6%
Total Cash Common Dividend
11.37%
28.22%
3.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,513
8,305
7,870
11,071
34,759
2025
8,320
8,238
10,186
- -
34,968
2026
7,443
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.69
1.88
0.01
2.44
6.01
2025
1.1
1.92
3.19
- -
8.29
2026
1.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
4.44
0.02
0.04
4.5
2025
- -
4.62
0.01
- -
4.65
2026
- -
- -
- -
- -
- -
Similar Companies
Soliton, Inc. (SOLY)
Modulight Oyj (MODU.HE)
Circassia Group Plc (CIR.L)
Neurotech International Limited (NTI.AX)
Advanced Oncotherapy plc (AVO.L)
Ion Beam Applications S.A. (IBAB.BR)
Business
Getinge AB (publ) develops and markets medical devices and therapy systems for operating rooms, intensive care units, and life science institutions worldwide. The company offers products and solutions across three primary business areas including Acute Care Therapies with ventilators, extracorporeal membrane oxygenation systems, intra-aortic balloon pumps, and heart-lung machines; Surgical Workflows encompassing operating tables, surgical lights, sterile reprocessing equipment such as washers, sterilizers like Poladus 150 low-temperature sterilizers, and drying cabinets; and Life Science featuring washers such as GEW 888 neo, single-use assemblies, sterile transfer bags like DPTE-BetaBag, and bioprocess development tools; complemented by digital health software including Talis clinical decision support and Advanta V12 covered stent systems. Getinge AB (publ), founded in 1904 and headquartered in Gothenburg, Sweden, employs approximately 12,000 people and operates in 40 countries with a global presence serving healthcare providers, hospitals, ambulatory surgery centers, pharmaceutical production, and research laboratories. Recent developments include the completion of the acquisition of Paragonix Technologies in September 2024 for approximately USD 253 million upfront to enhance organ preservation offerings in transplant markets; new product launches in 2024 such as Poladus 150 sterilizer, Talis software with 510(k) clearance, Advanta V12 EU MDR approval, GEW 888 neo washer, and renewable-source DPTE-BetaBag; the regaining of CE Mark for intra-aortic balloon pump Cardiosave in 2025 enabling resumed deliveries; and earlier acquisition of High Purity New England in 2023 to expand biopharma single-use assemblies.

Company News

APIChat

  • seekingalpha.com

    Getinge AB (publ) (GNGBY) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Analyzing Danaher (NYSE:DHR) and Getinge (OTCMKTS:GNGBY)

  • seekingalpha.com

    Getinge AB (publ) (GNGBY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    Contrasting AMN Healthcare Services (NYSE:AMN) & Getinge (OTCMKTS:GNGBY)

  • defenseworld.net

    Reviewing Getinge (OTCMKTS:GNGBY) & Pediatrix Medical Group (NYSE:MD)

  • seekingalpha.com

    Getinge AB (publ) (GNGBY) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q3 2024 Earnings Call Transcript

  • reuters.com

    Getinge misses Q3 forecasts, weighed by quality and delivery issues

  • seekingalpha.com

    Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q3 2023 Earnings Call Transcript

  • seekingalpha.com

    Getinge: Turnaround Catalysts To Outperform Healthcare Peers

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q2 2023 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) CEO Mattias Perjos on Q2 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) CEO Mattias Perjos on Q1 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    Getinge AB's (GNGBF) CEO Mattias Perjos on Q3 2021 Results - Earnings Call Transcript